The reassessment of Leqembi’s safety data follows the agency’s previous recommendation of the drug for use in the EU.

Shares of BioArctic AB (STO:BIOA B) climbed 4.8% following the announcement of its partner Eisai's robust sales figures for ...

The EC requests CHMP to reassess new safety data that emerged after the positive opinion recommending the approval of ...

An international clinical trial aimed at preventing Alzheimer’s disease (AD) in young adults who are at risk of developing ...

Children who inherit genetic mutations from parents with early-onset Alzheimer’s typically show signs of dementia at the same ...

Following the president’s recent executive order dismantling diversity, equity, and inclusion policies, the main page for the ...

Research supporting the amyloid hypothesis—the idea that Alzheimer's is caused by a buildup of amyloid plaques in the ...

In the latest development, the European Commission has asked the EMA's human medicines committee, the CHMP, to take a look at ...

The FDA has approved the sBLA for once every 4 weeks lecanemab-irmb (Leqembi®) intravenous maintenance dosing.

The European Commission has requested its medicines regulator to consider safety information on Eisai and Biogen's ...

Novartis issued stronger guidance than Wall Street expected. Elsewhere, Eisai and Biogen’s Alzheimer’s drug will get a closer ...